NEW YORK, September 8 /PRNewswire-FirstCall/ -- Biocoral, Inc. (OTCBB-BCRA) announced today that recently the Japanese Patent Office (JPO) approved and granted a company patent called Device for Filtration of Cryoprecipitate and its Application. The patent was granted to Bio Holdings International Ltd., the Company's wholly owned subsidiary, under the patent number 3 491 898. The Patent will expire in 2015.
The JPO is officially part of the Ministry of Economy, Trade and Industry in Japan (METI) and contributes to the development of industry by securing and protecting the successful and creative development of structures for patents, etc.
The present invention provides a device with a filter bag for separating a liquid phase from a suspended solid phase in a biological fluid. The device can be used, for example, in the separation of a blood plasma cryoprecipitate. The cryoprecipitate includes substances which are of therapeutic interest, such as clotting factor VIII or the proteins and in particular fibrinogen, fibronectin and factor VIII. Factor VIII is used in the treatment of haemophilia type A. The device permits the preparation of the Company's Autologus Biological Surgical Glue by using a proprietary single use device that assures the purity of the product, further protecting the patient from any complications.
The Company's Autologous Biological Surgical Glue is prepared using the patient's own blood, in a closed system, eliminating immunologic problems and the risk of blood-borne disease transmission such as, for example, HIV and hepatitis. In contrast, all surgical glues currently on the market (whether autologous or homologous) require foreign proteins such as thrombin or antifibrinolitic agents. The Company's Autologous Biological Surgical Glue has more complete clotting and platelet factors than conventional surgical glues, and by closely reconstituting naturally occurring events during repair, the adhesive yields superior treatment of tissue defects.
The Company's Autologous Biological Surgical Glue's superiority is further enhanced by its growth factors. These biological agents have been shown to speed tissue regeneration, thereby decreasing the recovery period after surgery. These advantages include enhanced plastic surgery results and improved graft take, notably in connection with the use of Biocoral(R) implants.
Nasser Nassiri, the Chairman and Chief Executive Officer of Biocoral, Inc. commented that, "This Patent was filed in Japan in 1995 and was in examination for approximately nine years before being granted. The grant of this Patent will protect the Company's Autologus Biological Glue technology in Japan where the company is looking to develop its product. In addition, our technology underlying our device is protected by strong patents in many countries. All of our patent applications have already been granted and issued by the official government patent offices in the countries where they were filed, including 17 European Community countries, Canada, Australia, and in the United States by the US Department of Commerce Patent and Trademark Office".
Nasser Nassiri further commented that, "Clinical trials have been done especially for skin replacement and skin grafts eliminating the need for protein based skin grafts. In its use to date in European trials, the Autologous Biological Surgical Glue has been shown to be clinically safe and effective. The Company plans to continue with its clinical trials to examine the use of the Autologous Biological Surgical Glue for cosmetic applications, utilizing respected plastic surgeons in Europe and the United States."
Biocoral, Inc., a Delaware corporation, is an international biomaterials "tissue-engineering" company specializing in the research and development of proprietary health care patented high technology and biomaterials. Through its subsidiaries, the Company researches, develops, manufactures and commercializes bone graft substitutes and other high tech patented biomaterials in a number of countries outside the United States. Biocoral, Inc. through its subsidiaries has developed the additional titles of patents for various applications and uses of its products, such as osteoporosis remediation, autologous glue, and combination with growth factor, among others. With these patent title applications in various countries in the European Community, Canada, the United States, Japan, Australia, and Switzerland, the Company owns more than 185 patent applications around the world, and approximately 140 of these have thus far been granted by various countries' official government patent offices, including most European Community countries, Canada, Australia, Japan and in the United States by the US Department of Commerce Patent and Trademark Office.
The information contained in this press release, including any "forward looking" statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 contained herein, should be reviewed in conjunction with the Company's Annual Report on Form 10-KSB and other publicly available information regarding the Company, copies of which are available from the Company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and such statements, including risks and uncertainties related thereto that are unpredictable and outside of the influence and/or control of the Company.